Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6901552 | 0.87 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1GLATSHRTP53 | |
| SCHEMBL6908386 | 0.85 | MLYCD (0.43) | MLYCDALDH1A1TSHRKMT2AOPRM1 | |
| SCHEMBL8858955 | 0.85 | ALDH1A1 (0.57) | MLYCDSMN1; SMN2ALDH1A1GLATSHR | |
| SCHEMBL10541028 | 0.85 | MLYCD (0.49) | MLYCDSMN1; SMN2ALDH1A1GLATSHR | |
| SCHEMBL4348518 | 0.84 | MLYCD (0.48) | MLYCDSMN1; SMN2ALDH1A1GLATSHR | |
| Hydrochloric Acid SCHEMBL5967266 | 0.84 | MLYCD (0.48) | MLYCDSMN1; SMN2ALDH1A1GLATSHR | |
| SCHEMBL6906900 | 0.83 | ALDH1A1 (0.45) | MLYCDALDH1A1TSHROPRM1 | |
| SCHEMBL8439016 | 0.83 | ALDH1A1 (0.47) | MLYCDSMN1; SMN2ALDH1A1GLATSHR | |
| SCHEMBL5353769 | 0.83 | ALDH1A1 (0.51) | MLYCDSMN1; SMN2ALDH1A1GLATSHR | |
| SCHEMBL6470937 | 0.82 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1GLATSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6824786-B2 | TOPICAL APPLYING COSMETIC | YU RUEY J (US) | 2004-11-30 | — | — | US | claimed |
| EP-1455734-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | Yu, Ruey J., Dr. (US) | 2004-09-15 | — | — | EP | claimed |
| US-20030108496-A1 | Compositions comprising phenyl-glycine derivatives | YU RUEY J (US) | 2003-06-12 | — | — | US | claimed |
| WO-2003045338-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | YU RUEY J (US) | 2003-06-05 | — | — | WO | claimed |
| US-6824786-B2 | TOPICAL APPLYING COSMETIC | YU RUEY J (US) | 2004-11-30 | — | — | US | disclosed |
| EP-1455734-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | Yu, Ruey J., Dr. (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030108496-A1 | Compositions comprising phenyl-glycine derivatives | YU RUEY J (US) | 2003-06-12 | — | — | US | disclosed |
| WO-2003045338-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | YU RUEY J (US) | 2003-06-05 | — | — | WO | disclosed |
| US-5821255-A | REGULATING THE SECRETION OF CORTICOTROPIN, BETA-ENDORPHIN OR PEPTIDES DERIVED FROM PROOPIOMELANOCORTIN | SANOFI (FR) | 1998-10-13 | — | — | US | disclosed |
| US-5602132-A | USEFUL IN TREATMENT OF PATHOLOGIES INVOLVING CORTICOTROPIN RELEASING FACTOR | SANOFI (FR) | 1997-02-11 | — | — | US | disclosed |
| CN-1127252-A | Branched-amino-sbustituted thiazoles, processes for their preparation and the pharmaceutical compositions which contain them | SANOFI SA (FR) | 1996-07-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108496-A1 | Compositions comprising phenyl-glycine derivatives | GRHPR, ARL1, SUCLG1 | MLYCD 1460/4885SMN1; SMN2 4727/4885ALDH1A1 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.